Merck Sharp + Dohme Corp.

Merck + Co., Inc.

International Flavors & Fragrances Inc.

Vincent Colandrea

Jeffrey John Hale

Scott D Edmondson

Rajan Anand

Petr Vachal

Liping Wang

Michael G Monteleone

Ping Liu

John S Debenham

Cheng Zhu

Lin Chu

Bing Li

Christina B Madsen-Duggan

James Francis Dropinski

Lehua Chang

Guizhen Dong

Deyou Sha

Fengqi Zhang

Nam Fung Kar

Kake Zhao

Alexander J Kim

Joshua G McCoy

Andrew William Stamford

Tesfaye Biftu

Anubhav P S Narula

Thomas F Walsh

George A Doherty

Anthony T Levorse, Jr

Ann E Weber

Michael W Miller

Dong-Ming Shen

Harvey Wendt

Jinlong Jiang

Zhicai Wu

Robert R Wilkening

Danqing D Feng

Iyassu Sebhat

Lin Yan

Duane E DeMong

Harold B Wood

Gregori J Morriello

Bowei Wang

Adam P Closson

Milana M Maletic

XiaoXia Qian

Ping Chen

Wanying Sun

Benjamin Amorelli

Richard Berger

William Bert Geiss

Christopher Joseph Sinz

John J Acton, Iii

Jinyou Xu

Pei Huo

Jacqueline D Hicks

Lan Wei

Kenneth J Leavitt

Yuping Zhu

James M Apgar

Joel M Harris

Feng Ye

Jiaqiang Cai

Debra L Ondeyka

Gary J Mertz

Bart Harper

Yi Zang

Alejandro Crespo

Zhiqiang Guo

Zhiyong Hu

Jason W Szewczyk

Anthony Mastracchio

Robert J Mathvink

Deodialsingh Guiadeen

Jonathan E Wilson

Matthew John Clements

Christopher R Moyes

Yong Huang

Xiaoxing Du

Weiguo Quan

Iyare E Amegor

Rongqiang Liu

Aaron Zwicker

Greg J Morriello

Megan Macala

Irene E Legiec

Leslie Toth

Maud Reiter

Anubhav PS Narula

Jr Anthony T Levorse

Iyare Amegor

The present invention relates to novel compounds and their use as fragrance materials.

Organoleptic compounds

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Inhibitors of HIF prolyl hydroxylase

The present invention relates to a novel compound and its use as fragrance material.

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Substituted benzopiperazines as CETP inhibitors

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 

Cyclic azabenzimidazole derivatives useful as anti-diabetic agents

The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydrofuropyridones

The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydro-1H-pyrrolo fused pyridones

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of &#x3b2;3-adrenoceptor. 

Pyrrolidine derived beta 3 adrenergic receptor agonists

The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists

The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Growing community of inventors

North Brunswick, NJ, United States of America

Vincent Colandrea